Search for content, post, videos

AstraZeneca’s Farxiga granted Priority Review in the US

Mene Pangalos
AstraZeneca’s Farxiga (dapagliflozin) has been granted Priority Review in the US for the treatment of new or worsening chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The Food and Drug Administration (FDA) grants Priority Review to regulatory submissions for med
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.